Interprofessional Management of Hypophosphatasia

softbones October 28, 2020

0 Comments

To read more please click on the link below.
Read Article

Categories: Scientific Publications

Tags: alkaline phosphatase, asfotase alfa, enzyme replacement therapy, hypophosphatasia, Metabolic bone diseases, Therapeutic drug monitoring, Tissue-nonspecific alkaline phosphatase

Related Articles

Gene Therapy for Hypophosphatasia: Current Management and Future

To read more please click on the link below. Read Article

Margaret Robb August 15, 2024

0 Comments

Not just a carrier: Clinical presentation and management of patients with heterozygous disease‐causing alkaline phosphatase (ALPL) variants identified through expanded carrier screening

To read more please click on the link below.Read Article

Denise Goodbar August 8, 2023

0 Comments

Physical therapy management of infants and children with hypophosphatasia

To read more please click on the link below. Read Article

softbones October 28, 2020

0 Comments

Clinical, radiographic and biochemical characteristics of adult hypophosphatasia

To read more please click on the link below. Read Article

softbones October 28, 2020

0 Comments

Neurological Symptoms in Hypophosphatasia

To read more please click on the link below. Read Article

softbones October 28, 2020

0 Comments

Responses

You must be logged in to post a comment.

Mail Address (P.O Box)
The US Hypophosphatasia Foundation
141 Hawkins Place, #267
Boonton, NJ 07005, USA.

Organization

Programs

Community

Office Address (Location for meetings and events)
1719 NJ-10, Suite 315
Parsippany, NJ 07054

Follow Us on Social Media!

Disclaimer: This Website is owned by Soft Bones, Inc. All materials contained in this Website (the “Materials”) are either owned by or licensed to us and are protected by intellectual property and other laws. We retain all proprietary rights to the Materials. This Website is copyrighted. All rights are reserved. Except as expressly authorized by us, any use, copy, reproduction, display, performance, modification or retransmission of the Materials is strictly prohibited.